Coya Therapeutics (COYA) Competitors $6.67 -0.05 (-0.74%) Closing price 04:00 PM EasternExtended Trading$6.68 +0.00 (+0.07%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. CYRX, HUMA, ATXS, PRTA, RCKT, FHTX, GLUE, AURA, ALT, and ABEOShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include CryoPort (CYRX), Humacyte (HUMA), Astria Therapeutics (ATXS), Prothena (PRTA), Rocket Pharmaceuticals (RCKT), Foghorn Therapeutics (FHTX), Monte Rosa Therapeutics (GLUE), Aura Biosciences (AURA), Altimmune (ALT), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Its Competitors CryoPort Humacyte Astria Therapeutics Prothena Rocket Pharmaceuticals Foghorn Therapeutics Monte Rosa Therapeutics Aura Biosciences Altimmune Abeona Therapeutics CryoPort (NASDAQ:CYRX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Does the media prefer CYRX or COYA? In the previous week, CryoPort had 12 more articles in the media than Coya Therapeutics. MarketBeat recorded 17 mentions for CryoPort and 5 mentions for Coya Therapeutics. CryoPort's average media sentiment score of 0.89 beat Coya Therapeutics' score of 0.38 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CYRX or COYA? CryoPort currently has a consensus price target of $11.11, suggesting a potential upside of 41.54%. Coya Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 147.38%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in CYRX or COYA? 92.9% of CryoPort shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 10.0% of CryoPort shares are held by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, CYRX or COYA? CryoPort has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Is CYRX or COYA more profitable? Coya Therapeutics has a net margin of 0.00% compared to CryoPort's net margin of -50.15%. CryoPort's return on equity of -11.03% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CryoPort-50.15% -11.03% -5.54% Coya Therapeutics N/A -48.88%-43.32% Which has stronger valuation and earnings, CYRX or COYA? Coya Therapeutics has lower revenue, but higher earnings than CryoPort. Coya Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoPort$228.38M1.72-$114.76M-$2.34-3.35Coya Therapeutics$3.55M31.43-$14.88M-$1.07-6.23 SummaryCryoPort beats Coya Therapeutics on 8 of the 15 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.39M$3.03B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A21.1828.1120.03Price / Sales31.43339.44461.57200.15Price / CashN/A43.2336.5559.01Price / Book2.818.368.655.90Net Income-$14.88M-$55.19M$3.25B$258.66M7 Day Performance14.80%5.89%4.20%2.23%1 Month Performance12.67%17.63%10.82%12.76%1 Year Performance-9.38%5.09%34.70%19.36% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics1.9065 of 5 stars$6.67-0.7%$16.50+147.4%-5.2%$112.39M$3.55M0.006News CoverageAnalyst ForecastCYRXCryoPort1.7838 of 5 stars$7.48+11.4%$11.11+48.6%-7.0%$373.54M$228.38M-3.181,186HUMAHumacyte1.6564 of 5 stars$2.31+0.2%$11.71+408.2%-66.9%$357.55M$1.57M-3.34150News CoverageAnalyst ForecastATXSAstria Therapeutics1.9456 of 5 stars$6.28+0.2%$30.00+378.1%-42.8%$353.56MN/A-3.3530Positive NewsPRTAProthena3.8424 of 5 stars$6.52+3.6%$31.50+383.5%-72.0%$351.30M$135.16M-3.14130Positive NewsRCKTRocket Pharmaceuticals4.8449 of 5 stars$3.28+4.6%$18.60+467.9%-87.2%$349.72MN/A-1.25240Trending NewsAnalyst ForecastGap DownFHTXFoghorn Therapeutics2.2035 of 5 stars$6.25+2.5%$12.13+94.0%-1.0%$347.65M$22.60M-4.59120News CoveragePositive NewsGLUEMonte Rosa Therapeutics2.0209 of 5 stars$5.64-3.3%$15.33+172.1%+29.8%$346.61M$75.62M70.4590AURAAura Biosciences2.4319 of 5 stars$6.82+0.7%$22.00+222.8%-23.8%$342.59MN/A-3.5950News CoveragePositive NewsALTAltimmune2.0849 of 5 stars$4.21+3.8%$18.20+332.8%-34.4%$341.07M$20K-3.3450ABEOAbeona Therapeutics3.7464 of 5 stars$6.57-2.7%$19.25+193.2%+31.7%$336.87MN/A-5.1990 Related Companies and Tools Related Companies CryoPort Competitors Humacyte Competitors Astria Therapeutics Competitors Prothena Competitors Rocket Pharmaceuticals Competitors Foghorn Therapeutics Competitors Monte Rosa Therapeutics Competitors Aura Biosciences Competitors Altimmune Competitors Abeona Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.